Trial Profile
A Multi-Center, Prospective, Observational, Extension Trial Following DURECT Protocol C803-017 to Investigate the Long-term Safety of SABER™-Bupivacaine Following Arthroscopic Shoulder Surgery
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jun 2022
Price :
$35
*
At a glance
- Drugs Bupivacaine (Primary)
- Indications Postoperative pain
- Focus Adverse reactions
- Sponsors DURECT Corporation
- 07 Apr 2017 New trial record